The LEAP-001 study evaluated the combination of Keytruda plus Lenvima for the first-line treatment of patients with advanced or recurrent endometrial carcinoma whose disease is mismatch repair ...
The first opinion recommends the approval of Keytruda in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the first-line treatment of adult patients with ...